Skip to main content

Table 3 Prognostic factors for local control (LC), Locoregional control (LRC) and metastasis-free survival (MFS)

From: Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III non-small cell lung cancer

  Local relapse Locoregional relapse
Variable Subhazard Ratio (SHR, 95% CI) p-value Subhazard Ratio (SHR, 95% CI) p-value
Gender
 Male (n = 35) 1 p = 0.2 1 p = 0.5
 Female (n = 11) 0.5 [0.1–1.6]   0.7 [0.3–1.9]  
Histology
 Non squamous (n = 24) 1 p = 0.3 1 p = 0.9
 Squamous (n = 22) 1.48 [0.6–3.2]   0.9 [0.5–1.7]  
Age
  < 66 years (n = 23) 1 p = 0.4 1 p = 0.9
  ≥ 66 years (n = 23) 1.4 [0.5–3.7]   0.9 [0.5–2]  
Period between irradiations
  > 24 months (n = 20) 1 p = 0.8 1 p = 0.1
  ≤ 24 months (n = 25) 1.1 [0.4–2.9]   1.8 [0.8–3.9]  
 Missing value (n = 1)     
  > 12 months (n = 36) 1 p = 0.8 1 p = 0.5
  ≤ 12 months (n = 9) 1.09 [0.3–3.6]   1.3 [0.5–3.5]  
 Missing value (n = 1)     
Dose of reirradiation
 BED > 130 Gy (n = 28) 1 p = 0.9 1 p = 0.09
 BED ≤130 Gy (n = 18) 0.9 [0.3–2.5]   1.8 [0.9–3.9]  
 BEDmin ≤50 Gy (n = 22) 1 p = 0.16 1 p = 0.06
 BEDmin > 50 Gy (n = 23) 0.5 [0.2–1.3]   0.5 [0.2–1.05]  
SABR duration
  ≥ 6 days (n = 25) 1 p = 0.4 1 p = 0.7
  < 6 days (n = 20) 1.5 [0.56–4.11]   0.9 [0.4–1.8]  
Chemotherapy after reirradiation
 Yes (n = 10) 1   1  
 No (n = 36) 1.6 [0.4–5.5] p = 0.4 1.6 [0.7–3.9] p = 0.2
Tumor size
  < 33 mm (n = 22) 1   1  
  ≥ 33 mm (n = 21) 1.58 [0.6–4.1] p = 0.3 1.6 [0.8–3.5] p = 0.18
 Missing value (n = 3)     
GTV Volume
  < 13 mL (n = 22) 1   1  
  ≥ 13 mL (n = 22) 1.49 [0.57–3.95] p = 0.4 1.83 [0.87–3.82] p = 0.10
 Missing value (n = 2)     
SABR duration
  ≥ 6 days (n = 25) 1 p = 0.4 1 p = 0.7
  < 6 days (n = 21) 1.51 [0.56–4.1]   0.87 [0.42–1.79]  
Number of fractions
  ≤ 3 (n = 16) 1 p = 0.09 1 p = 0.9
  > 3 (n = 30) 2.85 [0.85–9.6]   0.99 [0.47–2.1]  
Dose per fraction
  > 12 (n = 23) 1 p = 0.8 1 p = 0.2
  ≤ 12 (n = 22) 0.93 [0.35–2.44]   1.54 [0.74–3.21]  
Performans Status - ECOGa
 1 (n = 11) 1 p = 0.7 1 p = 0.19
 0 (n = 27) 0.78 [0.2–2.9]   1.8 [0.7–4.4]  
 Missing value (n = 8)     
Location of relapse
 Peripheral (n = 22) Central 1 p = 0.03 1 p = 0.9
  (n = 24) 3.2 [1.1–9.5]   0.9 [0.4–2.1]  
Primary stage (at first irradiation)
 IIIA (n = 21) 1 p = 0.6 1 p = 0.11
 IIIB (n = 25) 1.2 [0.5–3.2]   1.8 [0.9–3.7]  
In-field relapse
 No (n = 17) 1 p = 0.2 1 p = 0.2
 Yes (n = 29) 2 [0.7–5.9]   1.6 [0.7–3.6]  
In-field relapse and central tumors
No (n = 26) 1 p = 0.04 1 p = 0.8
Yes (n = 19) 2.8 [1.1–7.3]   0.9 [0.4–1.9]  
Adjuvant chemotherapy
 No (n = 36) 1 p = 0.4 1 p = 0.2
 Yes (n = 10) 1.6 [0.5–5.5]   1.6 [0.7–3.8]  
GTV coverage
  < 95% (n = 22) 1 p = 0.1 1 p = 0.07
  ≥ 95% (n = 24) 0.45 [0.17–1.18]   0.5 [0.2–1.06]  
PTV coverage
  < 90% (n = 23) 1 p = 0.17 1 p = 0.04
  ≥ 90% (n = 23) 0.5 [0.19–1.32]   0.4 [0.2–0.98]  
  1. aAt time of stereotactic ablative radiotherapy; ECOG = Eastern Cooperative Oncology Group